Ann Mullally: Expect to See Lots More Gene Therapy in Medicine in the Years Ahead
Ann Mullally, Professor at Stanford University School of Medicine, Division Chief of Hematology at Stanford Department of Medicine, Principal Investigator at Mullally Lab, shared Stanford Department of Medicine‘s post on LinkedIn:
“Expect to see lots more gene therapy in medicine in the years ahead!
One of many inspiring messages from Katherine High during her visit to Stanford Division of Hematology this week – a trailblazer in treating hemophilia with gene therapy, it was an honor to host Dr. High with Stanford Department of Medicine and to learn more about her pioneering work and exciting career!”
Stanford Department of Medicine shared a post on LinkedIn:
“Gene therapy pioneer Katherine High, delivered the Stanley Schrier Lecture at this week’s Medicine Grand Rounds.
High is the co-founder of Spark Therapeutics, Inc., winner of the 2026 Breakthrough Prize in Life Sciences and leader of the team that won FDA approval for Luxturna, the first gene therapy for an inherited disease.”
Stay updated with Hemostasis Today.
-
Nov 13, 2026, 03:21Abdul Muqtadir Abbasi: Iron Deficiency Beyond Anemia and the Importance of Finding the Cause
-
Nov 13, 2026, 03:05Marc Carrier: Aspirin vs Anticoagulants for VTE Prevention After Joint Replacement
-
Nov 13, 2026, 02:28Julia Sjöberg: ROCK1 Inhibition and Red Blood Cell Recovery After Chemotherapy
-
Nov 13, 2026, 02:07Tonie Reincke: Understanding Deep Vein Thrombosis and Vascular Health
-
Nov 13, 2026, 01:52Akshita Singh: The Remarkable Process of Blood Clotting
-
Nov 12, 2026, 22:52Milka Koupenova: The Role of Platelet RIG-I in Regulating Thrombotic Responses
-
Nov 12, 2026, 22:50Arun V J: Why Has India Still Not Achieved 100% Voluntary Blood Donation?
-
Nov 12, 2026, 22:49Sickle Cell Disease Deserves to Be Prioritised in Ghana – ISCC
-
Nov 12, 2026, 22:47Samir Kumar Beura: Delighted to Serve as a Topic Editor for a Research Topic in Frontiers in Neuroscience